Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243346 · ClinicalTrials.gov registry record · Phase 2
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
A Phase 2 study of D842-related Mutant GIST, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT01243346: Completed Phase 2 study of D842-related Mutant GIST, sponsored by Arog Pharmaceuticals.
NCT01243346 is a Phase 2 study of D842-related Mutant GIST that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01243346, a Phase 2 study of D842-related Mutant GIST, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.
Primary Outcome
To determine the response rate of patients with advanced D842V mutant GIST, when treated with Crenolanib (CP-868,596). Response will primarily be determined by RECIST criteria
Conditions Studied
Interventions
- DRUG Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
Study Locations (2)
Oregon
- Knight Cancer Institute, Oregon Health and Science University - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT01243346 record still lists
NCT01243346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with D842-related Mutant GIST appearing as the primary indexed condition, and to 1 intervention - of which Crenolanib besylate (CP-868,596-26), Dose: 140mg BID is the first listed.
NCT01243346 reports a single indexed study location in Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01243346 about?
NCT01243346 is a clinical study titled "Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene". This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.
What is the current status of trial NCT01243346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-04. Estimated completion is 2014-07.
What conditions does trial NCT01243346 study?
This clinical trial studies the following conditions: D842-related Mutant GIST.
What interventions are being tested in trial NCT01243346?
The interventions under investigation include: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID (DRUG).
Who is sponsoring clinical trial NCT01243346?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01243346 being conducted?
This trial has 2 study locations across Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01243346's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia